Franklin Resources
NTLA icon

Franklin Resources’s Intellia Therapeutics NTLA Stock Holding History

Franklin Resources’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$954K Buy
77,467
+67,138
+650% +$839K ﹤0.01% 2331
2026
Q2 		$175K Buy
+10,329
New +$145K ﹤0.01% 2881
2025
Q4 		– Sell
-10,239
Closed -$177K – 3222
2025
Q3 		$177K Buy
+10,239
New +$126K ﹤0.01% 2857
2025
Q2 		– Sell
-12,751
Closed -$90.7K – 3099
2025
Q1 		$90.7K Sell
12,751
-3,383
-21% -$34.2K ﹤0.01% 2819
2024
Q4 		$188K Sell
16,134
-271
-2% -$4.23K ﹤0.01% 2661
2024
Q3 		$320K Buy
16,405
+1,538
+10% +$35.5K ﹤0.01% 2465
2024
Q2 		$333K Sell
14,867
-2,377
-14% -$56.6K ﹤0.01% 2399
2024
Q1 		$474K Buy
17,244
+928
+6% +$25.8K ﹤0.01% 2275
2023
Q4 		$497K Buy
16,316
+2,372
+17% +$68.2K ﹤0.01% 1946
2023
Q3 		$441K Sell
13,944
-3,567
-20% -$138K ﹤0.01% 1983
2023
Q2 		$714K Buy
17,511
+7,642
+77% +$310K ﹤0.01% 1791
2023
Q1 		$368K Sell
9,869
-921
-9% -$36.1K ﹤0.01% 1795
2022
Q4 		$376K Buy
10,790
+298
+3% +$14.2K ﹤0.01% 1784
2022
Q3 		$588K Sell
10,492
-456,181
-98% -$28.3M ﹤0.01% 1647
2022
Q2 		$24.2M Sell
466,673
-499,965
-52% -$25.4M 0.01% 748
2022
Q1 		$70.2M Sell
966,638
-162,943
-14% -$13.8M 0.03% 511
2021
Q4 		$134M Buy
1,129,581
+150,131
+15% +$18.8M 0.05% 388
2021
Q3 		$131M Buy
979,450
+589,302
+151% +$89.2M 0.05% 389
2021
Q2 		$63.2M Buy
390,148
+376,767
+2,816% +$29.3M 0.02% 571
2021
Q1 		$1.07M Buy
13,381
+5,004
+60% +$336K ﹤0.01% 1466
2020
Q4 		$455K Buy
+8,377
New +$304K ﹤0.01% 1569
2017
Q2 		– Sell
-300,000
Closed -$4.23M – 1520
2017
Q1 		$4.23M Hold
300,000
– – ﹤0.01% 1131
2016
Q4 		$3.93M Hold
300,000
– – ﹤0.01% 1129
2016
Q3 		$5.11M Hold
300,000
– – ﹤0.01% 1101
2016
Q2 		$6.4M Buy
+300,000
New +$7.98M ﹤0.01% 1059

Other funds holding NTLA

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $17.4B AUM 41.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Tarrytown, New York $180M AUM 18.92% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $8.04B AUM 33.34% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Franklin Resources's NTLA Position: Q3 2026 in Review

Franklin Resources increased its Intellia Therapeutics (NTLA) stake by 650% in Q3 2026, buying an estimated $839K and bringing the position to 77,467 shares worth $954K. The position accounts for ﹤0.01% of the portfolio, ranked #2331.

Franklin Resources first reported a position in NTLA in Q2 2016 and has held it in 25 quarters since. The position peaked at $134M in Q4 2021. 222 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.

  • Franklin Resources held 77,467 shares of Intellia Therapeutics worth $954K as of Q3 2026.
  • Franklin Resources bought 67,138 Intellia Therapeutics shares in Q3 2026, an estimated $839K.
  • Intellia Therapeutics made up ﹤0.01% of Franklin Resources's portfolio in Q3 2026, its #2331 holding.
  • Franklin Resources first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 25 quarters since.
  • Franklin Resources's Intellia Therapeutics position peaked at $134M in Q4 2021.
  • 222 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.

Based on Franklin Resources's 13F filing for Q3 2026, filed 12 Nov 2026.